Clinical Trials Browser

Expanded_access × Genitourinary × 1 year × Clear all

NCT06443944 2026-03-06

An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCG

Available

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urologic Neoplasms

NCT04091295 2026-03-04

BLESSED: Expanded Access for DNG64-CAR-V for Advanced Pancreatic Cancer, Sarcoma and Carcinoma of Breast

Available

BreastGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Chondrosarcoma, Chordoma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Osteosarcoma, Neurofibrosarcoma

NCT06836648 2026-02-25

Single Patient Compassionate Use of X-PACT in Salvage Treatment of Prostate Cancer

Available

Genitourinary

Prostatic Neoplasms

NCT06877676 2026-02-13

Pre-Approval Expanded Access Study for TAR-200 Treating Physician Use

Approved for marketing

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT04566393 2026-01-28

Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies

Available

CNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Glioblastoma, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT03756311 2026-01-23

Expanded Access to NanoPac

No longer available

GenitourinaryThoracic

Lung Neoplasms, Prostatic Neoplasms

NCT06810141 2026-01-14

ResQ132EX-NMIBC: Expanded Access Use of Recombinant Bacillus Calmette-Guérin in Nonmuscle Invasive Bladder Cancer

Available

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT03523338 2025-12-10

An Expanded Access Protocol for Apalutamide Treatment of Participants With Non-Metastatic Castration-Resistant Prostate Cancer

No longer available

Genitourinary

Prostatic Neoplasms

NCT05974410 2025-10-02

Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients

Available

BreastCNSGastrointestinalGenitourinaryGynecologicLymphoidSarcoma

Brain Neoplasms, Breast Neoplasms, Carcinoma, Squamous Cell, Glioblastoma, Hodgkin Disease, Lymphoma, Non-Hodgkin, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Stomach Neoplasms

NCT05064306 2025-08-01

131I-omburtamab for the Treatment of Central Nervous System/Leptomeningeal Neoplasms in Children and Young Adults

No longer available

CNSGastrointestinalGenitourinaryOther solid neoplasmSarcoma

Medulloblastoma, Meningeal Neoplasms, Wilms Tumor, Neuroblastoma, Pinealoma, Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Rhabdoid Tumor

NCT06090331 2025-07-08

89Zr-DFO-girentuximab Expanded Access Program (EAP)

Available

Genitourinary

Carcinoma, Renal Cell

NCT05401214 2025-06-13

Pre-approval Access Single Patient Request for Niraparib / Abiraterone Acetate Combination (Nira/AA Combination)

Approved for marketing

Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT05650476 2025-06-12

Pre-approval Single-patient Expanded Access for Talazoparib (PF-06944076)

Available

Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT04100694 2025-05-20

Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor

Approved for marketing

BreastGastrointestinalGenitourinaryHead & NeckThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Neoplasms, Unknown Primary, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma